The European medicines regulator said that a higher rate of death and disease complications in recent trials meant the ...
This delay is attributed to procedural issues at the European Medicines Agency that have implications for the review process of lecanemab. Lecanemab has been under EMA review since January 2023 for ...
The European Medicines Agency (EMA) has initiated a review of Tecovirimat SIGA, also called TPOXX, a medicine used to treat mpox. This follows emerging clinical trial data suggesting a lack of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback